Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736393 | 0.91 | SIRT6 (0.52) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL3541959 | 0.84 | POLB (0.47) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL3939908 | 0.84 | POLB (0.47) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL15434058 | 0.84 | POLB (0.57) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL9964597 | 0.83 | AURKA (0.51) | — | |
| SCHEMBL3542244 | 0.82 | LMNA (0.63) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL30356891 | 0.82 | POLB (0.55) | ALDH1A1POLBLMNASMN1; SMN2KMT2A | |
| SCHEMBL3551013 | 0.81 | ALDH1A1 (0.56) | ALDH1A1POLBLMNAKMT2ACYP3A4 | |
| SCHEMBL4521440 | 0.81 | LMNA (0.58) | ALDH1A1POLBLMNASMN1; SMN2RAB9A | |
| SCHEMBL1560662 | 0.81 | LMNA (0.49) | ALDH1A1POLBLMNASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | ALDH1A1 422/4885POLB 3906/4885LMNA 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.